---
title: "Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Announces Date for Extraordinary General Meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/267133403.md"
description: "Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. will hold an extraordinary general meeting on 23 December 2025 in Shenzhen, China, to consider and pass an ordinary resolution. The original content was published via the Issuer Information Service of the Hong Kong Stock Exchange on November 24, 2025."
datetime: "2025-11-24T08:35:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/267133403.md)
  - [en](https://longbridge.com/en/news/267133403.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/267133403.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/267133403.md) | [繁體中文](https://longbridge.com/zh-HK/news/267133403.md)


# Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Announces Date for Extraordinary General Meeting

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. has announced that it will hold an extraordinary general meeting on 23 December 2025 at its office in Shenzhen, Guangdong Province, China. The meeting will consider and, if thought fit, pass an ordinary resolution. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. published the original content used to generate this news brief via via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251124-11925684), on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [NEPTUNUS (000078.CN)](https://longbridge.com/en/quote/000078.CN.md)

## Related News & Research

- [Shanghai Henlius Biotech to Hold Board Meeting on 2025 Final Results and Dividend Recommendation](https://longbridge.com/en/news/277590866.md)
- [Huadong Medicine Obtains Greenlight for Cancer Drug Trial](https://longbridge.com/en/news/277569784.md)
- [Is It Time To Reassess Immunocore (IMCR) After Recent Biotech Progress And Valuation Signals](https://longbridge.com/en/news/277329555.md)
- [10:35 ETCell-free DNA offers early warning for bloodstream infections in kids with leukemia](https://longbridge.com/en/news/277491859.md)
- [08:03 ETDecentralized Clinical Trial Validates Novel "Fasting Mimetic" Formulation for Cardiometabolic Health](https://longbridge.com/en/news/277468910.md)